Loading…
← CockpitCompetitor Analysis › KIDS OrthoPediatrics Corp.Open in the cockpit ↗

OrthoPediatrics Corp.KIDSCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 97
Mkt cap
$826M
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$13.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-13.4 pp
WACC 9.1%
Hurdle
n/a
no reverse DCF
Next earnings
112 days
10 Mar 2027
Close · USD$31.65
1D+0.8%
1W-6.0%
1M+34.7%
3M+20.7%
6M+71.1%
YTD+78.2%
1Y+93.9%
ATR %4.7%
Beta0.94
52w lowhigh8.3% off high

What OrthoPediatrics does

Employees: 602

OrthoPediatrics at a glance

Size OrthoPediatrics (KIDS) is a United States Health Care company (Medical Specialties) with a market value of $826M, the 2348th largest of 3,085 United States companies the cockpit tracks. Shares closed at $31.65 on 18 Nov 2026.

Performance Over six months the shares gained 71.1%, against -15.1% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 16.1% over the last twelve months (peer median +5.8%); the operating margin is -8.2% (peer median 10.2%).

Valuation It trades at 3.4× enterprise value to sales against a peer median of 3.6× (10th cheapest of 21).

Capital Return on invested capital runs 13.4 points below its cost of capital (9.1% WACC).

Short interest Short interest is 2.9% of the free float (30 Oct 2026).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026KIDS 172Peer median 85
Six months, rebased to 100: OrthoPediatrics against the median of its 20 peers (local-currency closes).

OrthoPediatrics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$264M$236M$205M$149M$122M
Revenue growth—+15%+38%+22%—
Gross profit$172M$152M$130M$93.9M$77.6M
EBITDA$1.26M-$8.81M-$10.8M-$8.38M-$8.31M
Net income-$33.9M-$39.6M-$37.8M-$21.0M$1.24M
Free cash flow$2.89M-$16.0M-$41.3M-$43.9M-$31.8M
Capital expenditure$11.3M$13.1M$14.9M$19.0M$10.0M
Total debt$106M$117M$84.7M$23.8M$16.7M

Quarterly statements and history in the cockpit →

OrthoPediatrics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%6888051187688068MCAPAMS6033673600096530301602688656002658688277SETLBBNX688767MLAB688575CTKB1302KIDS6-month return →1-month return →
Up and to the right = strong over both horizons. OrthoPediatrics is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×5×10×6888051187688068MCAPAMS6033673600096530301602688656002658688277SETLBBNX688626688767MLAB688575KIDSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. OrthoPediatrics is the large dot.

OrthoPediatrics competitors and peer comparison

How OrthoPediatrics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

OrthoPediatrics against its 20 peers (data as of 18 Nov 2026)
MeasureKIDSPeer medianRank in peer set
1-month return+34.7%-5.1%highest of 21
6-month return+71.1%-15.1%2nd highest of 21
Distance from 52-week high-8.3%-40.3%4th highest of 21
Revenue growth (TTM)+16.1%+5.8%6th highest of 21
Operating margin-8.2%10.2%5th lowest of 21
EV / Sales3.4×3.6×10th cheapest of 21
ROIC minus cost of capital-13.4 pp-1.6 pp5th lowest of 21
Net debt / EBITDA48.5×0.1×most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%3.4×n/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%6.8×35.6%+17.1%
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%1.0×-6.4%+6.6%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%9.6×n/an/a
MedCap MCAP.STSweden$811M-4%+17%15%3.6×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%3.0×20.0%+21.4%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%0.7×-14.6%-1.3%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%1.6×-7.1%+11.3%
Seegene 096530.KSSouth Korea$808M-26%+13%13%1.2×-6.7%-15.9%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%12.0×11.1%+4.6%
HOB Biotech 688656.SSChina$858M-33%+6%7%13.7×37.6%+12.4%
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%3.3×16.8%+2.9%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%21.7×n/an/a
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%7.7×n/an/a
Beta Bionics BBNXUnited States$779M+42%+44%-73%4.3×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%7.2×n/an/a
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%10.4×n/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%3.6×21.3%+13.2%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%3.1×2.0%+12.7%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%2.6×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%3.2×9.6%+15.5%

Questions

Which companies are OrthoPediatrics's closest peers?
The cockpit's peer set: Ningbo Jansen Superconducting Technologies (688805.SS), Cofoe Medical Technology (1187.HK), Beijing Hotgen Biotech (688068.SS), MedCap (MCAP.ST), Advanced Medical Solutions (AMS.L), Cisen Pharmaceutical (603367.SS), Modern Dental (3600.HK), Seegene (096530.KS).
Is OrthoPediatrics expensive compared with its peers?
On ev / sales it trades at 3.4× against a peer median of 3.6×, 10th cheapest of 21 in its peer set.
How has OrthoPediatrics stock performed?
Over six months to 18 Nov 2026 the shares returned +71.1% against -15.1% for the median peer; over one year +93.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.